Looking at the Issues and Opportunities of the Orphan Drug Regulatory, Pricing and Reimbursement landscape in Canada. If you are interesting in joining the study, contact email@example.com to participate!
C-MAP™ Canadian Drug Benefit Plans Reference Guide 2014 Edition
The C-MAP™ Canadian Drug Benefit Plans Reference Guide provides detailed information on the formulary listing policies and procedures of the ten provincial prescription drug programs and four federal drug programs. Detailed overviews of Provincial Cancer Programs, the pan-Canadian Oncology Drug Review (pCODR), the Patented Medicine Prices Review Board (PMPRB), the Canadian Agency for Drugs and Technologies in Health (CADTH), Federal/ Provincial/ Territorial Initiatives, and private drug plans in Canada are also included. An extensive section on the Common Drug Review (CDR) provides a comprehensive description of the CDR process including CDR rationale for the Canadian Drug Expert Committee (CDEC) decisions and CDR submission forms and templates available online. In addition, the special report Pharmaceutical Pricing and Reimbursement in Canada provides an overview of the Canadian pharmaceutical pricing and reimbursement environment.
New features of the 2014 Edition include:
- Pharmaceutical Reimbursement in the Canadian Territories
- CADTH Patient Input Processes
- The Pan-Canadian Pricing Alliance
- Detailed Submission Requirements for Private Drug Plans
- Human Drug Advisory Panel Submission Procedures
Sections on Canadian Blood Services and Héma-Québec Submission Requirements and Drug Review Processes have also been expanded in the 2014 Edition.
Subscribers also receive password-protected access to the online version of C-MAP™ Canadian Drug Benefit Plans Reference Guide 2014 Edition, including manufacturers’ submission forms and templates.